During the past decade, Quanzhou First Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Quanzhou First Hospital" #1 sponsor was "Fujian Medical University" with 2 trials, followed by "Anji Pharma" with 1 trials sponsored, "Ark Biosciences Inc." with 1 trials sponsored, "Beijing Tiantan Hospital" with 1 trials sponsored and "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Quanzhou First Hospital" #1 collaborator was "Beijing Chao Yang Hospital" with 1 trials as a collaborator, "China-Japan Friendship Hospital" with 1 trials as a collaborator, "Covance" with 1 trials as a collaborator, "First Affiliated Hospital of Chongqing Medical University" with 1 trials as a collaborator and "First Hospital of China Medical University" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Quanzhou First Hospital" are "Acute Ischemic Stroke" (1 trials), "Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma" (1 trials), "Breast Neoplasm" (1 trials), "Coronary Heart Disease" (1 trials) and "Esophageal Carcinoma" (1 trials). Many other conditions were trialed in "Quanzhou First Hospital" in a lesser frequency.

Most popular intervention types in "Quanzhou First Hospital" are "Drug" (8 trials), "Procedure" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "AK0529" (1 trials), "AK105 injection" (1 trials), "Albumin-Bound Paclitaxel" (1 trials), "Alteplase" (1 trials) and "Anlotinib hydrochloride capsule" (1 trials). Other intervention names were less common.

The vast majority of trials in "Quanzhou First Hospital" are 9 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 6 active trials in "Quanzhou First Hospital". 2 are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 2 completed trials in Quanzhou First Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Quanzhou First Hospital, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".